Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009–2019: A Study of the National (Nationwide) Inpatient Sample
2022/04/14 by Mina Suh, Naimisha Movva, Xiaohui Jiang +7 · 131 citations
Medicine · #Acute Bronchiolitis #Bronchiolitis #COVID-19 Clinical Research Studies #Confidence interval #Cystic Fibrosis Research Advances #Demography #Diagnosis code #Environmental health #Internal medicine #Medicine #Pediatrics #Population #Respiratory system #Respiratory viral infections research
paper · pdf · doi:10.1093/infdis/jiac120
published in The Journal of Infectious Diseases 226(Supplement_2), S154-S163 (Oxford University Press)
openalex publication_date 2022/04/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/30
Abstract
BACKGROUND: This study describes leading causes of hospitalization, including respiratory syncytial virus (RSV), in United States infants (<1 year) from 2009 through 2019. METHODS: Within the National (Nationwide) Inpatient Sample (NIS) data, hospitalizations were determined by primary diagnosis using International Classification of Diseases, Ninth or Tenth Revision codes. RSV was defined as 079.6, 466.11, 480.1, B97.4, J12.1, J20.5, or J21.0. Bronchiolitis was defined as 466.19, J21.8, or J21.9. Leading causes overall and by sociodemographic variables were identified. The Kids' Inpatient Database (KID) was used for confirmatory analyses. RESULTS: Acute bronchiolitis due to RSV (code 466.11 or J21.0) was the leading primary diagnosis, accounting for 9.6% (95% confidence interval [CI], 9.4%-9.9%) and 9.3% (95% CI, 9.0%-9.6%) of total infant hospitalizations from January 2009 through September 2015 and October 2015 through December 2019, respectively; it was the leading primary diagnosis in every year accounting for >10% of total infant hospitalizations from December through March, reaching >15% in January-February. From 2009 through 2011, acute bronchiolitis due to RSV was the leading primary diagnosis in every birth month. Acute bronchiolitis due to RSV was the leading cause among all races/ethnicities, except Asian/Pacific Islanders, and all insurance payer groups. KID analyses confirmed these results. CONCLUSIONS: Acute bronchiolitis due to RSV is the leading cause of US infant hospitalizations.
Citations
Cited by
- SHEA practice update: infection prevention and control (IPC) in residential facilities for pediatric patients and their families
- The Story behind the Science: On the discovery of respiratory syncytial virus
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
- Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024
- Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis
- The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis. [europepmc]
- Systematic Literature Review of Respiratory Syncytial Virus Laboratory Testing Practices and Incidence in United States Infants and Children <5 Years of Age. [europepmc]
- Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019. [europepmc]
- Epidemiology and molecular characteristics of respiratory syncytial virus (RSV) among italian community-dwelling adults, 2021/22 season. [europepmc]
- Respiratory Syncytial Virus in Veneto Region: Analysis of Hospital Discharge Records from 2007 to 2021. [europepmc]
- Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak. [europepmc]
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. [europepmc]
- Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic. [europepmc]
- Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. [europepmc]
- What U.S. Obstetricians Need to Know About Respiratory Syncytial Virus. [europepmc]
- Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. [europepmc]
- COVID-19, Influenza, and RSV in Children and Adults: A Clinical Comparative Study of 12,000 Cases. [europepmc]
- Observations of Respiratory Syncytial Virus (RSV) Nucleic Acids in Wastewater Solids Across the United States in the 2022-2023 Season: Relationships with RSV Infection Positivity and Hospitalization Rates. [europepmc]
- Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month. [europepmc]
- Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes. [europepmc]
- Paid Family Leave and Prevention of Acute Respiratory Infections in Young Infants. [europepmc]
- Infant-derived human nasal organoids exhibit relatively increased susceptibility, epithelial responses, and cytotoxicity during RSV infection. [europepmc]
- Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis. [europepmc]
- Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. [europepmc]
- Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options. [europepmc]
- Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates. [europepmc]
- Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023-2024. [europepmc]
- RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera. [europepmc]
- Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024. [europepmc]
- Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. [europepmc]
Related